摘要
制药行业是国内保持多年快速发展的朝阳行业，1978年至2000年，制药行业产值年均递增16.6％，成为国民经济中发展最快的行业之一。由于多年来的市场无序竞争和地方保护主义，制药行业普遍存在规模小、科研开发能力弱、主要以仿制生产为主的严重问题。为了加速中国由制药大国向制药强国的战略转变，应对加入WTO后跨国制药企业的竞争，制药企业必须立足国情，加强相互之间的分工合作，通过制药企业间的兼并重组，发展大集团、大公司，或做大做强，或做奇做精，主动拓展新形势下的生存空间。由于市场瞬息万变，制药企业兼并重组的方式往往是多元的，即多种方式的混合使用。如在“强强联合”后再“大吃小”，以迅速实现企业市场垄断地位提高的目标。如“三九集团”收购“雅安三九”“长征制药”；“哈药集团”参股“慈航制药”；“太太药业”收购“丽珠集团”等等。可以预见，为应对加入WTO后跨国制药集团的竞争，我国制药企业进行兼并重组是必然趋势，也是抗击全球经济一体化市场风浪的最终出路。
本文以白沙集团下属企业“珠海金沙(湖南)制药有限公司(以下简称金沙制药)”的兼并重组实例为标的进行实证研究，探讨和寻求我国制药行业兼并重组的模式和对策。
Pharmacy trade is a domestic fast-developing vigorous trade for many years. From 1978 to 2002, the output value of pharmacy trade increased progressively 16.6% every year and became one of trades with the fastest developing speed in national economy. Because of the unordered competition of market for many years and local protectionism, there are serious problems for most pharmacy trade, such as small scales of enterprises, weak capacity for research and developing and taking model production mainly. In order to accelerate the strategic change of China from the pharmaceutical big country to powerful country and meet the competition of the international pharmacy enterprises after the accession to WTO, pharmacy trade must base on the national conditions to strengthen the division and cooperation and through merger and recombination among pharmacy enterprises to develop the big group or big company to make it strongly or greatly or very precisely and expand the living space under the new situation on the new situation. Because the market changes fast, the ways for merger and recombination of pharmacy enterprises are often plural, many kinds of ways are used. For example, "eats small one "after" combination among the strong ones", so as to realize those monopolizing goal whose status are raised by market rapidly. Such as" San Jiu Group" purchases" Yaan San Jiu and Long March Pharmaceutical Co.,Ltd."," Hayao Group" participates in "Hachi Pharmaceutical Co.,Ltd." by shares; "Taitai Pharmaceutical Co.,Ltd. "purchases" Livzou Group", etc. We could predict that, in order to deal with the competition of international pharmaceutical groups after the accession to WTO, it is an inexorable trend that pharmacy trade of our country merges and recombines. It is the final outlet of resisting stormy waves of market of global economic integration too.
This paper uses the merger and recombination this text instance of Zhuhai Jinsa(Hunan) pharmaceutical Co., Ltd.(hereafter referred to as Jinsa pharmacy) (belongs to Beshiney Group) to go on the real research and try to probe into and seek the modes and countermeasures merged and recombined in the pharmacy trade of our country.
引文
[1] 林燕。全球市场的战略联营与收购．北京：中国大百科全书出版社，1998
[2] 牟发章．世界制药巨头兼并重组风云又起．中国医药经济报，1999，6
[3] 靳天鹏．上市公司兼并重组评析中国股市收购兼并重组典型案例展望．深圳：海天出版社，1998
[4] 刘伟，高明华．转型期的国有企业重组．上海：上海远东出版社，1999
[5] 黄湘源．重组魔方．珠海：珠海出版社，1999
[6] 段克竞，王纬．兼并重组浪潮与中国对策．北京：世界知识出版社，1999
[7] 孙黎，刘平．收购风云国际公司购并与产权交易实录．深圳：海天出版社，2000
[8] [美]布伦特·斯考克罗夫特．重组的世界．南京：江苏人民出版社，2000
[9] 历勇．500强企业CEO是如何管理企业．中国经营报，1999，10
[10] Richard Johnson. Twenty Five Ways to Improve Sales and Profits without Spending and Extra Dime on Advertising. Seattle: Crisp Publications, Inc, 1999
[11] 潘岳．资产重组的政策与途径．北京：经济科学出版社，1997
[12] 胡建绩．产权重组．上海：上海译文出版社，1997
[13] [英]沃拉德．收购与接管．北京：宇航出版社．1998
[14] Opler T. Operating Performance in Leveraged Buyout: Evidence from 1985～1989. Financial Management 1992,21:27～34
[15] Jeffrey C Hooke. A guide for Acquiring. Cambridge: Cambridge Publications Inc, 1999
[16] Opler T. Controlling Financial Distress Costs in Leveraged Buyout with Financial Innovations. Financial Management, 1993,22:79～90
[17] Chotigeat T, Paandy I M, Kim D J. Venture Capital Investment Evaluation in Emerging Markers. Multinational Business Review, 1997, (9):54～62
[18] David J Denis. Organization Form and the Consequences of Highly LeveragedTransactions: Kroger' s Capitalization and Safeway' s LBO. Journal of Financial Economics, 1994,36(2):193～224
[19] [美]P S桑德萨那姆，艾德里安·巴克利．兼并重组与收购．北京：中国人民大学出版社，1997
[20] P Asquith. Event Risk, Covenants, and Bondholder Returns in Leveraged Buyouts. Journal of Financial Econmics, 1990,27(1):195～213
[21] 孙耀唯，萧金成，蒋兆理．企业重组理论与实务．北京：石油工业出版社，1998
[22] [日]小岛郁夫．企业兼并重组．北京：中信出版社，2001
[23] [英]彼得·诺兰．战略重组全球产业强强联手宏观透视．上海：文汇出版社，1999
[24] F R Lichtenberg. The Effects of Leveraged Buyouts on Productivity and Related Aspects of Firm Behavior. Journal of Financial Economics, 1990,27(1):165～193
[25] 约瑟夫·克拉林格．兼并重组与收购交易管理．北京：中国人民大学出版社，2000
[26] Opler T. The Determinants of Leveraged Buyout Activity: Free Cash Flow vs Financial Distress Costs. Journal of Finance, 1993, (48):1985～1999
[27] [美]布莱思·伯区别勒．大收购．海口：海南出版社，1997
[28] Auerbach A. Merger and Acquisition. Chicago: University of Chicago Press, 1988
[29] 姜彦福．管理技巧兼并重组收购．北京：世界图书出版公司，1998
[30] 罗锐韧．公司购并与资产重组．北京：国际文化出版公司，2001
[31] Matthew Kropf. Corporate Reorganizations and Non-cash Auctions. Journal of Finance, 2000, (4):17～39
[32] 吴晓波．我国药品生产企业的概览．中国医药商情，2000，(1)：20～24
[33] 堂清．关于中药现代化产业化发展战略的几点构思．中国中医药信息杂志，2001，(3)：1～3
[34] 彭国瑞．中药进入国际市场的策略分析．中医药管理杂志，2000，(6)：4～55
[35] 王志英．我国医药消费市场潜力惊人．中国消费报，2000，8
[36] 温元凯．资产重组案例来自中国千家上市公司的报告．北京：经济日报出版社，2000
[37] 魏杰．资产重组与股份化国有企业改革的两大突破点．石家庄：河北人民出版社，1998
[38] Farree, Joseph, Shapriro Carl. Horizontal Mergers. American Economic Review, 1991,81(4):1007～1011
[39] Charles A Scharf. Acquisitions, Mergers, Sales, Buyouts and Takeovers. New Jersey: Prentice Hall Inc, 1984
[40] Henry G Manne. Mergers and Market for Corporate Control. Journal of Political Economy, 1965, (73):10～20
[41] Easterbrook, Fischel. The Economic Structure of Corporate Law. Cambridge: Harvard University Press, 1991
[42] 许子枋．企业兼并重组风险研究．长沙：湖南人民出版社，2000
[43] 张邦辉．企业收购实录．北京：中国物价出版社，1998
[44] [美]佩帕德．经营过程重组．北京：中信出版社，2000
[45] [美]J弗雷德·威斯通．兼并重组重组与公司控制．北京：经济科学出版社，1998